Eucrates Biomedical Acquisition Corp. Unit
EUCRU
EUCRU was delisted on the 26th of April, 2023.
19 hedge funds and large institutions have $43.5M invested in Eucrates Biomedical Acquisition Corp. Unit in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 5 closing their positions.
15% less capital invested
Capital invested by funds: $50.9M → $43.5M (-$7.42M)
17% less funds holding
Funds holding: 23 → 19 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$112K |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$46.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$4M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$2.01M |
| 3 |
HM
HealthCor Management
New York
|
-$1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$562K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$331K |
EUCRU Hedge Fund Activity: Q2 2021 in Review
19 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q2 2021, worth a combined $43.5M — down 15% from $50.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EUCRU and 1 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $112K. The largest seller was Altium Capital Management, exiting entirely with an estimated $4M sold.
- 19 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q2 2021, down from 23 in Q1 2021.
- Funds reported $43.5M of Eucrates Biomedical Acquisition Corp. Unit stock for Q2 2021, down 15% quarter-over-quarter.
- 1 fund opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q2 2021 and 5 closed out, a net change of -4 holders.
- The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q2 2021 was Citadel Advisors, an estimated $112K added.
- The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q2 2021 was Altium Capital Management, an estimated $4M sold.
Based on aggregated 13F filings for Q2 2021.